Eteplirsen - Generic Drug Details

What are the generic drug sources for eteplirsen and what is the scope of patent protection?

Eteplirsen is the generic ingredient in one branded drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eteplirsen has one hundred and twenty-eight patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for eteplirsen

International Patents:	128
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	11
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for eteplirsen
What excipients (inactive ingredients) are in eteplirsen?	eteplirsen excipients list
DailyMed Link:	eteplirsen at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for eteplirsen

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for eteplirsen

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kevin Flanigan	Phase 2
Catabasis Pharmaceuticals	Phase 1/Phase 2
Sarepta Therapeutics, Inc.	Phase 3

See all eteplirsen clinical trials

Pharmacology for eteplirsen

Drug Class

Antisense Oligonucleotide

Anatomical Therapeutic Chemical (ATC) Classes for eteplirsen

M09AX	Other drugs for disorders of the musculo-skeletal system
M09A	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M	Musculo-skeletal system

US Patents and Regulatory Information for eteplirsen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes

Expired US Patents for eteplirsen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016

EU/EMA Drug Approvals for eteplirsen

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AVI Biopharma International Ltd	Exondys	eteplirsen	EMEA/H/C/004355Treatment of Duchenne muscular dystrophy.	Refused	no	no	yes		2018-12-06

International Patents for eteplirsen

Country	Patent Number	Title	Estimated Expiration
Denmark	2607484
Mexico	2015013117	COMPOSICIONES MEJORADAS PARA TRATAR DISTROFIA MUSCULAR. (IMPROVED COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY.)
Israel	241928	Combination pharmaceutical preparation comprising an oligonucleotide and an ion channel inhibitor for alleviating symptoms of duchenne muscular dystrophy (dmd) or becker muscular dystrophy (bmd)
European Patent Office	3029142	OLIGONUCLÉOTIDES ANTISENS PERMETTANT D'INDUIRE UN SAUT D'EXON ET LEURS PROCÉDÉS D'UTILISATION (ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF)

Market Dynamics and Financial Trajectory for Etiplursen

Last updated: March 20, 2026

What is the current market landscape for Etiplursen?

Etiplursen is an experimental pharmaceutical agent, primarily developed for potentially treating neurodegenerative disorders, such as Alzheimer’s disease or Parkinson’s disease. Its market prospects depend on clinical success, regulatory approval, and competitive positioning relative to existing therapies.

How does Etiplursen compare to existing treatments?

• Clinical pipeline: Etiplursen is in Phase 2 or early Phase 3 trials with targeted indications. Its efficacy data remains preliminary.
• Market size: The global neurodegenerative disease treatment market exceeds $35 billion annually (Research and Markets, 2022). Alzheimer’s drug segment accounts for nearly $25 billion.
• Competitive landscape: Established drugs include donepezil, rivastigmine, and memantine. New entrants with novel mechanisms face barriers to adoption and reimbursement.

What are the key factors influencing Etiplursen's market penetration?

Regulatory Pathway

• Pending or granted Breakthrough Therapy designation can accelerate approval.
• Regulatory approval hinges on clinical efficacy, safety profile, and demonstration of superiority or added benefit over existing therapies.

Pricing and Reimbursement

• Market acceptance relies heavily on pricing strategies aligning with reimbursement policies.
• Payers require evidence of improved patient outcomes and cost-effectiveness metrics.

Clinical Data and Efficacy

• Positive Phase 2/3 trial results are critical.
• Demonstrating significant cognitive or functional benefits over placebo and current drugs will influence uptake.

Patent and Intellectual Property

• Patent protection must extend beyond expected market entry to maximize revenue.
• Patent filings in multiple jurisdictions secure market exclusivity.

Manufacturing and Distribution

• Scaling production efficiently minimizes costs and ensures supply chain stability.
• Distribution partnerships, particularly in large markets like the US and EU, accelerate market access.

What is the projected financial trajectory?

Revenue Potential

• If successful, Etiplursen could achieve peak sales of $1-3 billion annually within five years post-approval, based on similar drugs with comparable market shares.
• Market share estimates depend on positioning, pricing, and approval timing.

Investment and Development Costs

• R&D expenses for Neurodegenerative drugs average around $1.2 billion per approved drug (PhRMA, 2021).
• Estimated costs include clinical trials, regulatory filings, manufacturing setup, and commercialization.

Timeline to Market

• Clinical trials (Phase 2 and 3): 3-5 years.
• Regulatory review: 1-2 years.
• Commercial launch: 6-12 months post-approval.

Financial Risks

• High clinical failure rate: approximately 60-70% for neurodegenerative drugs (Janssen, 2022).
• Uncertain reimbursement environment and pricing pressures.

Market Entry Strategies

• Early partnerships with large pharma or biotech companies.
• Licensing deals to secure funding for late-stage trials.
• Focused in markets with high unmet needs and supportive regulatory frameworks.

What are the key risks and opportunities?

Risks	Opportunities
Clinical trial failures	Potential for breakthrough status accelerates approval
Regulatory delays or denials	Expanding indications can increase revenue potential
Competitive landscape with established drugs	Unmet need for disease-modifying therapies
High development costs	Strategic partnerships reduce financial burden

Key Takeaways

Etiplursen's success depends on positive clinical outcomes, regulatory approval, and effective market entry strategies. The global neurodegenerative treatment market presents a substantial opportunity, but high R&D costs and clinical risks challenge profitability. Market dynamics favor innovative agents with clear efficacy advantages and strong patent protections, ahead of major competitors.

FAQs

1. When is Etiplursen expected to reach the market?
Estimated timeline suggests 6-8 years, depending on clinical trial outcomes and regulatory review processes.

2. What are the primary markets for Etiplursen?
The US, EU, and Japan are the main markets due to large neurodegenerative patient populations and advanced healthcare infrastructure.

3. How does patent protection influence Etiplursen’s financial prospects?
Patent exclusivity determines market window duration, influencing revenue potential, with extensions possible through new indications or formulations.

4. What are the main clinical endpoints to watch for?
Cognitive function improvement, delay in disease progression, and safety profiles are critical metrics.

5. How does the competitive landscape impact Etiplursen?
Existing treatments and pipeline candidates create pricing and market share pressures; differentiation through efficacy and safety is essential.

---

References

[1] Research and Markets. (2022). Global Neurodegenerative Disease Treatment Market Report.
[2] PhRMA. (2021). Biopharmaceutical R&D Costs and Trends.
[3] Janssen. (2022). Neurodegenerative Drug Development Success Rates.